Health Insurance Fund Reforms ADHD Medication Reimbursement: End to Mandatory Trial Treatments

The Health Insurance Fund is changing how attention-deficit hyperactivity disorder medications are reimbursed, freeing patients from the obligation to first try less effective medications. The change takes effect next month and ends the bureaucratic requirement for trial therapy that forced patients to wait weeks for effective treatment.

The Health Insurance Fund has made an important decision to reform the reimbursement system for attention-deficit hyperactivity disorder (ADHD) medications, bringing significant relief to thousands of Estonian patients. The new rules take effect next month.

The previous system required patients to undergo mandatory trial therapy – before obtaining reimbursement for a more suitable and effective medication, they had to spend weeks testing less effective alternatives. The Health Insurance Fund's new decision will eliminate this bureaucratic requirement.

The change is particularly important for patients for whom mandatory trial therapy was an emotionally and physically draining process. ADHD is a neurological condition that significantly affects daily functioning, and delays in appropriate treatment can mean considerable difficulties in both work and personal life.

The Health Insurance Fund's decision reflects a broader trend in Estonia's healthcare system – to reduce administrative burden and prioritise patient needs. Simplifying the medication reimbursement system allows doctors and patients to work together to make the best treatment decisions more quickly without unnecessary bureaucratic obstacles.